Fierce Life Sciences · Business

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.

Episodes

FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)

22 Jun 2026

20m

Page 2

Follow this podcast in Podwise

Open in Podwise

The Top Line

Episodes

FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)

Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones

Behind the headlines of ASCO 2026

Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)

Boston, China and the future of biotech

BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions

Health execs persevere in new policy landscape

Revisiting Pharma’s tariff reality

Scaling theranostics through access, safety and trust (Sponsored)

A pivotal time for an RNA pioneer

Accelerating clinical trials with precision logistics (Sponsored)

Can Trump’s deal with the UK become a model for similar drug price agreements?

Biomarkers are reshaping oncology trial design (Sponsored)

Fixing failed spray-dried formulations faster (Sponsored)

Roivant’s CEO thinks China is a ‘red herring’

The top 10 pharma R&D budgets of 2025

An update on the pharma industry’s reshoring effort

Pulse check on Lilly's GLP-1 fortunes

Avoiding 11th hour surprises in clinical trials (Sponsored)

What Xaira is building after its $1B fundraise